NCT04487847 (PICture) is a Phase 1, PHASE2 clinical trial of 18F-PSMA-1007 PET/CT in Prostate Cancer, sponsored by Radboud University Medical Center.

Who is sponsoring NCT04487847?

NCT04487847 is sponsored by Radboud University Medical Center.

What drugs are being tested in NCT04487847?

Interventions in NCT04487847: 18F-PSMA-1007 PET/CT.

What condition does NCT04487847 study?

NCT04487847 studies Prostate Cancer.

Is NCT04487847 still recruiting?

NCT04487847 is currently completed. Last updated 16 January 2025.

Last reviewed 2025-01-16 · How we verify

NCT04487847: PICture

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

18F-PSMA-1007 PET Imaging to Detect Primary Prostate Cancer

Completed Phase 1, PHASE2 Last updated 16 January 2025

What this trial tests

Phase 1, PHASE2 trial testing 18F-PSMA-1007 PET/CT in Prostate Cancer in 75 participants. Completed in 31 December 2023.

Timeline

1 September 2020

Primary endpoint
28 February 2023

31 December 2023

Quick facts

Lead sponsor	Radboud University Medical Center
Phase	Phase 1, PHASE2
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	diagnostic
Enrollment	75
Start date	1 September 2020
Primary completion	28 February 2023
Estimated completion	31 December 2023
Sites	1 location across Netherlands

Drugs / interventions tested

18F-PSMA-1007 PET/CT

Conditions studied

Prostate Cancer — all drugs for Prostate Cancer →

Sponsor

Radboud University Medical Center

Who can join

18 and older, male only, with Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To study the added value of 18F-PSMA-1007 PET to mpMRI in the detection of local prostate cancer lesions.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging.
Jadvar H, Calais J, Fanti S, Feng F, et al · · 2022 · cited 95× · PMID 34593595 · DOI 10.2967/jnumed.121.263262
Multiparametric MRI and <sup>18</sup>F-PSMA-1007 PET/CT for the Detection of Clinically Significant Prostate Cancer.
Privé BM, Israël B, Janssen MJR, van der Leest MMG, et al · · 2024 · cited 18× · PMID 38771185 · DOI 10.1148/radiol.231879
A cost-effectiveness study of PSMA-PET/CT for the detection of clinically significant prostate cancer.
Privé BM, Govers TM, Israël B, Janssen MJR, et al · · 2025 · cited 6× · PMID 40072531 · DOI 10.1007/s00259-025-07190-6
European Association of Nuclear Medicine October 20-23, 2021 Virtual.
· 2021 · cited 5× · PMID 34559267 · DOI 10.1007/s00259-021-05547-1
Incorporating PSMA-Targeting Theranostics Into Personalized Prostate Cancer Treatment: a Multidisciplinary Perspective.
Ng TSC, Gao X, Salari K, Zlatev DV, et al · · 2021 · cited 4× · PMID 34395293 · DOI 10.3389/fonc.2021.722277
Radionuclide Imaging of Cytotoxic Immune Cell Responses to Anti-Cancer Immunotherapy.
Lauwerys L, Smits E, Van den Wyngaert T, Elvas F. · · 2022 · cited 3× · PMID 35625811 · DOI 10.3390/biomedicines10051074
The false myth of "iodine allergy" also in nuclear medicine.
Gómez-Perales JL, García-Mendoza A. · · 2021 · cited 2× · PMID 34585268 · DOI 10.1007/s00259-021-05356-6
Prostate-specific Membrane Antigen PET: Standard Imaging in Prostate Cancer.
Jadvar H. · · 2022 · cited 1× · PMID 35608452 · DOI 10.1148/radiol.221074

Verify or expand the search:

Other recruiting trials for Prostate Cancer

Currently open trials in the same condition.

NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting

Other Radboud University Medical Center trials

Trials by the same sponsor.

NCT07485569 — Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial · Phase 1 · not yet recruiting
NCT07514325 — MR-guided Adaptive Stereotactic Radiotherapy for Endometrial Cancer · NA · not yet recruiting
NCT07530263 — Deposition of Inhaled Liposomal Amphotericin B in Chronic Pulmonary Aspergillosis (CPA) · Phase 1 · not yet recruiting
NCT07532577 — Intranasal Insulin to Prevent Intensive Care Unit Delirium · Phase 2, PHASE3 · not yet recruiting
NCT07504172 — Real-world Effectiveness and Dosing Patterns of Tirzepatide in People With Obesity · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04487847 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Radboud University Medical Center
Last refreshed: 16 January 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04487847.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing